Inclisiran: the first siRNA approved by European Medicines Agency for treatment of dyslipidemias
Authors:
Michal Vrablík
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in:
AtheroRev 2021; 6(1): 50-51
Category:
Sources
-
Ray KK, Wright RS, Kallend D. [ORION-10 and ORION-11 Investigators]. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020; 382(16): 1507–1519. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1912387>.
-
Raal FJ, Kallend D, Ray KK. [ORION-9 Investigators]. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020; 382(16): 1520–1530. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1913805>.
-
Informace dostupné z WWW: <https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2021 Issue 1
Most read in this issue
- Inclisiran: the first siRNA approved by European Medicines Agency for treatment of dyslipidemias
- Second consensus statement of European Atherosclerosis Society on low-density lipoproteins: statement of Czech Society for Atherosclerosis
- Low concentration of plasma cholesterol and type 2. diabetes mellitus
- Early cardiovascular risk intervention means cummulation of positive impacts in time